Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Boots recalls more medicines

Boots has recalled six more of its own-brand medicines and two Almus medicines due to the risk that plastic could have fallen into the bottles, the MHRA has announced

Boots has recalled six more batches of its own-brand medicines and one batch of Almus medicines due to the risk that plastic could have fallen into the bottles, the MHRA announced today (December 12).


The medicines watchdog issued a precautionary recall of medicines including children's paracetamol suspension, cough syrup, gripe mixture and ibuprofen suspension, two weeks after recalling five similar medicines.


Patients with queries about the recall should talk to their local Boots team, GP or the Boots customer care team

More on the MHRA

MHRA announces Boots recall of cough and cold medicines

MHRA urges caution in switching epilepsy drugs

MHRA warns of migraine injection contamination


The MHRA announced on November 26 Boots' concerns that a manufacturing fault in the tamper seal could have caused small pieces of plastic to fall into five batches of its cough and cold medicine brands.



Boots said this may have affected seven other batches of medicines (see right). The MHRA advised patients to return any of these batches purchased since September for a refund.


"This is a precautionary recall by Boots and there is a low risk of plastic being found in the bottles," said Adam Burgess, head of the MHRA's defective medicines reporting centre. "There is currently no evidence that people have had any problems with these medicines."


Patients who have queries over the recall are advised to speak to their local pharmacy team or GP, or they can call Boots' customer care team on 0800 915 0004.


 

The affected medicines

Recalled today:

● Boots Pharmaceuticals Paracetamol 6 Years Plus 250mg/5ml suspension 100m. Batch no: PL 00014/0619

● Boots Pharmaceuticals Tickly Cough Relief oral solution. Batch no: PL 00014/0550

● Boots Pharmaceuticals Paracetamol 3 Months Plus 120mg/5ml suspension 100ml. Batch no: PL 00014/0638

● Boots Pharmaceuticals Paracetamol 3 Months Plus 120mg/5ml suspension 200ml. Batch no: PL 00014/0660

● Boots Pharmaceuticals Cough Syrup 3 Months Plus. Batch no: PL 00014/0500

● Boots Pharmaceuticals Gripe Mixture 1 Month Plus. Batch no: PL 00014/5236

● Almus Paracetamol 250mg/5ml oral suspension. Batch no: PL 00014/0619

Recalled in November:

● Boots Pharmaceuticals Chesty Cough Relief 100mg/5ml oral solution. Batch no: PL 00014/0554

● Boots Pharmaceuticals Dry Cough Relief oral solution. Batch no: PL 00014/0550

● Boots Pharmaceuticals Mucus Cough Relief 100mg/5ml oral solution. Batch no: PL 00014/0554

● Boots Pharmaceuticals Paracetamol 6 years plus 250mg/5ml oral solution 200ml. Batch no: PL 00014/0619

● Boots Pharmaceuticals Ibuprofen 3 months plus 100mg/5ml oral suspension, strawberry flavour. Batch no: PL 00014/0652

● Almus Ibuprofen 3 Months Plus 100mg/5ml oral suspension strawberry flavour. Batch no: PL 00014/0652

Topics

         
Pharmacist Manager
Barnsley
£30 per hour

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD016698

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel